HLB Pep Co., Ltd. (KOSDAQ:196300)
South Korea
· Delayed Price · Currency is KRW 7,050.00
+70.00 (1.00%)
At close: Mar 9, 2026
HLB Pep Revenue
HLB Pep had revenue of 1.17B KRW in the quarter ending September 30, 2025, with 5.21% growth. This brings the company's revenue in the last twelve months to 4.89B, down -20.02% year-over-year. In the year 2024, HLB Pep had annual revenue of 6.23B with 11.02% growth.
Revenue (ttm)
4.89B
Revenue Growth
-20.02%
P/S Ratio
13.40
Revenue / Employee
n/a
Employees
n/a
Market Cap
65.52B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.23B | 618.09M | 11.02% |
| Dec 31, 2023 | 5.61B | -3.05B | -35.23% |
| Dec 31, 2022 | 8.66B | -1.60B | -15.63% |
| Dec 31, 2021 | 10.27B | 1.75B | 20.56% |
| Dec 31, 2020 | 8.52B | 2.24B | 35.67% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SunBio,Inc. | 2.17B |
| PanGen Biotech | 15.27B |
| Ark Solutions | 21.50B |
| CHA Vaccine Research Institute | 158.62M |
| Aptamer Sciences | 1.08B |
| EyeGene | 4.10B |
| NGeneBio | 9.98B |
| Naturalendo Tech | 21.87B |